Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aminolevulinic acid
Drug ID BADD_D00110
Description A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Indications and Usage Aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
Marketing Status approved
ATC Code L01XD04
DrugBank ID DB00855
KEGG ID D07567
MeSH ID D000622
PubChem ID 137
TTD Drug ID D0Y7ZD
NDC Product Code 46016-5450
UNII 88755TAZ87
Synonyms Aminolevulinic Acid | Acid, Aminolevulinic | Delta-Aminolevulinic Acid | Acid, Delta-Aminolevulinic | Delta Aminolevulinic Acid | Levulan | 5-Aminolaevulinate | 5 Aminolaevulinate | 5-Aminolevulinate | 5 Aminolevulinate | Aminolevulinic Acid Hydrochloride | Acid Hydrochloride, Aminolevulinic | Hydrochloride, Aminolevulinic Acid
Chemical Information
Molecular Formula C5H9NO3
CAS Registry Number 106-60-5
SMILES C(CC(=O)O)C(=O)CN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin tightness23.03.03.018--Not Available
Photodermatosis23.03.09.004--Not Available
Lymphatic disorder01.09.01.003--Not Available
Application site swelling08.02.01.027; 12.07.01.0270.001388%Not Available
Haemorrhage24.07.01.002--Not Available
Application site discolouration23.03.03.023; 12.07.01.030; 08.02.01.0300.000761%Not Available
Angiopathy24.03.02.007--Not Available
Induration08.01.03.020--Not Available
Brain neoplasm17.20.01.003; 16.30.01.003--Not Available
Cardiac disorder02.11.01.003--Not Available
Embolism24.01.01.009--
Infestation23.11.01.002; 11.09.01.001--Not Available
Mental disorder19.07.01.002--Not Available
Blood disorder01.05.01.004--Not Available
Hepatobiliary disease09.01.08.003--Not Available
Application site hypersensitivity12.07.01.014; 10.01.03.009; 08.02.01.0130.000381%Not Available
Skin abrasion23.03.11.018; 12.01.06.010--Not Available
Hyperpathia17.02.07.015--Not Available
Application site scab23.03.03.050; 12.07.01.042; 08.02.01.0420.000492%Not Available
Accidental exposure to product12.09.01.001--Not Available
Absence of immediate treatment response08.06.01.0350.000951%Not Available
Drug effect less than expected08.06.01.0360.000761%Not Available
Therapeutic product effect incomplete08.06.01.0520.000627%Not Available
The 4th Page    First    Pre   4    Total 4 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene